This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Bloch, Y., Arad, S., & Levkovitz, Y. (2014). World Journal of Biological Psychiatry, (Epub ahead of print).
This study explores the effect of Brainsway® Deep TMS (Transcranial Magnetic Stimulation) on adults who suffer from intractable Tourette Syndrome (TS). The study enrolled 12 patients and was held over 20 days. The study found no significant side effects, and indicated that Deep TMS is safe for treating TS. In the study, the subgroup who suffered from both TS and Obsessive Compulsive Disorder (OCD) experienced significant improvement – a beneficial result that also indicates that TS is not of a uniform nature.